Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/26442 |
Resumo: | Moreira Junior, Edson Duarte. Associação Obras Sociais Irmã Dulce / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil. a Clinical Research Group, Universidad del Rosario, Bogotá, Colombia b Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil c Foundation Clinical Research Center CIC, Medellín, Colombia d Research Center on Public Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico e Via Libre Association, Lima, Peru f Hospital Nacional Arzobispo Loayza, Lima, Peru g Departamento de Tocoginecologia da Universidade Federal do Paraná, Curitiba, Brazil h Centro de Investigaciones, Hospital Universitario San Ignacio, Bogotá, Colombia i Arké Estudios Clínicos S.A. de C.V., Mexico City, Mexico j Department of Obstetrics and Gynecology, Fundacion Valle del Lili, Cali, Colombia k Research Unit, Pablo Tobon Uribe Hospital, Medellin, Colombia l Departamento de Ginecología y Obstetricia Clínica Colsanitas, Fundación Universitaria Sanitas, Bogotá, Colombia mDepartment of Gynecology, Fundación Cardioinfantil, Bogotá, Colombia n CAFAM, Bogotá, Colombia o Department of Gynecology and Obstetrics, University of Santa Catarina, Florianópolis, Santa Catarina, Brazil p Gynecological Oncology Division Hospital Clinico San Borja Arriaran Universidad de Chile Campus Centro, Santiago, Chile q Department of Pediatrics, Universidad del Valle and Centro Medico Imbanaco, Cali, Colombia r Merck & Co., Inc., Kenilworth, NJ, USA |
id |
CRUZ_ff3aa88f7f2e78e16c44118ec02aa1c2 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/26442 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Sternberg, Ángela María RuizMoreira Junior, Edson DuarteRestrepo, Jaime A.Ponce, Eduardo LazcanoCabello, RobinsonSilva, ArnaldoAndrade, RosiresRevollo, FranciscoUscanga, SantosVictoria, AlejandroGuevara, Ana MaríaLuna, JoaquínPlata, ManuelDominguez, Claudia NossaFedrizzi, EdisonSuarez, EugenioReina, Julio C.Ellison, Misoo C.Moeller, ErinRitter, MichaelShields, ChristineCashat, MiguelPerez, GonzaloLuxembourg, Alain2018-05-15T12:46:02Z2018-05-15T12:46:02Z2018STEMBERG, Ángela María Ruiz et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Research, v. 5, p. 1-12, 2018.2405-8521https://www.arca.fiocruz.br/handle/icict/2644210.1016/j.pvr.2017.12.004Moreira Junior, Edson Duarte. Associação Obras Sociais Irmã Dulce / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil. a Clinical Research Group, Universidad del Rosario, Bogotá, Colombia b Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil c Foundation Clinical Research Center CIC, Medellín, Colombia d Research Center on Public Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico e Via Libre Association, Lima, Peru f Hospital Nacional Arzobispo Loayza, Lima, Peru g Departamento de Tocoginecologia da Universidade Federal do Paraná, Curitiba, Brazil h Centro de Investigaciones, Hospital Universitario San Ignacio, Bogotá, Colombia i Arké Estudios Clínicos S.A. de C.V., Mexico City, Mexico j Department of Obstetrics and Gynecology, Fundacion Valle del Lili, Cali, Colombia k Research Unit, Pablo Tobon Uribe Hospital, Medellin, Colombia l Departamento de Ginecología y Obstetricia Clínica Colsanitas, Fundación Universitaria Sanitas, Bogotá, Colombia mDepartment of Gynecology, Fundación Cardioinfantil, Bogotá, Colombia n CAFAM, Bogotá, Colombia o Department of Gynecology and Obstetrics, University of Santa Catarina, Florianópolis, Santa Catarina, Brazil p Gynecological Oncology Division Hospital Clinico San Borja Arriaran Universidad de Chile Campus Centro, Santiago, Chile q Department of Pediatrics, Universidad del Valle and Centro Medico Imbanaco, Cali, Colombia r Merck & Co., Inc., Kenilworth, NJ, USAMerck & Co., Inc., Kenilworth, NJ, USAAssociação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.Múltipla - ver em NotasA 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (> 99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden.engElsevierEfficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young womeninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHuman papillomavirusVaccineCervical cancerPersistent infection9vHPVinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/26442/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALSternberg A Efficacy, immunogenicity, and safety .....pdfSternberg A Efficacy, immunogenicity, and safety .....pdfapplication/pdf376128https://www.arca.fiocruz.br/bitstream/icict/26442/2/Sternberg%20A%20Efficacy%2c%20immunogenicity%2c%20and%20safety%20.....pdfd0a5a02156fc0ece7940d43baf637f8fMD52TEXTSternberg A Efficacy, immunogenicity, and safety .....pdf.txtSternberg A Efficacy, immunogenicity, and safety .....pdf.txtExtracted texttext/plain70955https://www.arca.fiocruz.br/bitstream/icict/26442/3/Sternberg%20A%20Efficacy%2c%20immunogenicity%2c%20and%20safety%20.....pdf.txtb22bb2485ef80249387d6addf52d2f1bMD53icict/264422023-03-15 14:34:06.605oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:06Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
title |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
spellingShingle |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women Sternberg, Ángela María Ruiz Human papillomavirus Vaccine Cervical cancer Persistent infection 9vHPV |
title_short |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
title_full |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
title_fullStr |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
title_full_unstemmed |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
title_sort |
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women |
author |
Sternberg, Ángela María Ruiz |
author_facet |
Sternberg, Ángela María Ruiz Moreira Junior, Edson Duarte Restrepo, Jaime A. Ponce, Eduardo Lazcano Cabello, Robinson Silva, Arnaldo Andrade, Rosires Revollo, Francisco Uscanga, Santos Victoria, Alejandro Guevara, Ana María Luna, Joaquín Plata, Manuel Dominguez, Claudia Nossa Fedrizzi, Edison Suarez, Eugenio Reina, Julio C. Ellison, Misoo C. Moeller, Erin Ritter, Michael Shields, Christine Cashat, Miguel Perez, Gonzalo Luxembourg, Alain |
author_role |
author |
author2 |
Moreira Junior, Edson Duarte Restrepo, Jaime A. Ponce, Eduardo Lazcano Cabello, Robinson Silva, Arnaldo Andrade, Rosires Revollo, Francisco Uscanga, Santos Victoria, Alejandro Guevara, Ana María Luna, Joaquín Plata, Manuel Dominguez, Claudia Nossa Fedrizzi, Edison Suarez, Eugenio Reina, Julio C. Ellison, Misoo C. Moeller, Erin Ritter, Michael Shields, Christine Cashat, Miguel Perez, Gonzalo Luxembourg, Alain |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Sternberg, Ángela María Ruiz Moreira Junior, Edson Duarte Restrepo, Jaime A. Ponce, Eduardo Lazcano Cabello, Robinson Silva, Arnaldo Andrade, Rosires Revollo, Francisco Uscanga, Santos Victoria, Alejandro Guevara, Ana María Luna, Joaquín Plata, Manuel Dominguez, Claudia Nossa Fedrizzi, Edison Suarez, Eugenio Reina, Julio C. Ellison, Misoo C. Moeller, Erin Ritter, Michael Shields, Christine Cashat, Miguel Perez, Gonzalo Luxembourg, Alain |
dc.subject.en.pt_BR.fl_str_mv |
Human papillomavirus Vaccine Cervical cancer Persistent infection 9vHPV |
topic |
Human papillomavirus Vaccine Cervical cancer Persistent infection 9vHPV |
description |
Moreira Junior, Edson Duarte. Associação Obras Sociais Irmã Dulce / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil. a Clinical Research Group, Universidad del Rosario, Bogotá, Colombia b Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil c Foundation Clinical Research Center CIC, Medellín, Colombia d Research Center on Public Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico e Via Libre Association, Lima, Peru f Hospital Nacional Arzobispo Loayza, Lima, Peru g Departamento de Tocoginecologia da Universidade Federal do Paraná, Curitiba, Brazil h Centro de Investigaciones, Hospital Universitario San Ignacio, Bogotá, Colombia i Arké Estudios Clínicos S.A. de C.V., Mexico City, Mexico j Department of Obstetrics and Gynecology, Fundacion Valle del Lili, Cali, Colombia k Research Unit, Pablo Tobon Uribe Hospital, Medellin, Colombia l Departamento de Ginecología y Obstetricia Clínica Colsanitas, Fundación Universitaria Sanitas, Bogotá, Colombia mDepartment of Gynecology, Fundación Cardioinfantil, Bogotá, Colombia n CAFAM, Bogotá, Colombia o Department of Gynecology and Obstetrics, University of Santa Catarina, Florianópolis, Santa Catarina, Brazil p Gynecological Oncology Division Hospital Clinico San Borja Arriaran Universidad de Chile Campus Centro, Santiago, Chile q Department of Pediatrics, Universidad del Valle and Centro Medico Imbanaco, Cali, Colombia r Merck & Co., Inc., Kenilworth, NJ, USA |
publishDate |
2018 |
dc.date.accessioned.fl_str_mv |
2018-05-15T12:46:02Z |
dc.date.available.fl_str_mv |
2018-05-15T12:46:02Z |
dc.date.issued.fl_str_mv |
2018 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
STEMBERG, Ángela María Ruiz et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Research, v. 5, p. 1-12, 2018. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/26442 |
dc.identifier.issn.pt_BR.fl_str_mv |
2405-8521 |
dc.identifier.doi.none.fl_str_mv |
10.1016/j.pvr.2017.12.004 |
identifier_str_mv |
STEMBERG, Ángela María Ruiz et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Research, v. 5, p. 1-12, 2018. 2405-8521 10.1016/j.pvr.2017.12.004 |
url |
https://www.arca.fiocruz.br/handle/icict/26442 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/26442/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/26442/2/Sternberg%20A%20Efficacy%2c%20immunogenicity%2c%20and%20safety%20.....pdf https://www.arca.fiocruz.br/bitstream/icict/26442/3/Sternberg%20A%20Efficacy%2c%20immunogenicity%2c%20and%20safety%20.....pdf.txt |
bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 d0a5a02156fc0ece7940d43baf637f8f b22bb2485ef80249387d6addf52d2f1b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009256868216832 |